Intermittent transcatheter therapy through a new indwelling catheter system for patients with hepatocellular carcinoma

Osamu Itano, Satoshi Itano, Hiroaki Nagamatsu, Rina Tsutsui, Akihiro Deguchi, Masanori Inoue, Seishi Nakatsuka

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Purpose: This paper describes the technical details of the new indwelling catheter system, which we refer to as System-i, and provides an overview of our experience with this system at our institution.

Materials and methods: The system is implanted via the left brachial artery. The feeding artery of the tumor is catheterized at each treatment, and the system can be used for multiple treatments via more than one feeding artery. Between January 2004 and January 2013, System-i was used to administer 398 treatments in 30 patients with hepatocellular carcinoma (HCC). The technical aspects and outcomes of treatment procedures were evaluated.

Results: Implantation was successful in all cases. System-i was used for a median number of 11 treatments per patient over a median period of 5.7 months, and 71.6 % of all treatments were administered on an outpatient basis.

Conclusion: System-i provides an effective and safe method for selective catheterization of feeding arteries for administration of transcatheter arterial chemoembolization or infusion in patients with HCC. Treatment regimens can be individualized without limiting the number of treatments or treatment locations, and patients can be treated on an outpatient basis.

Original languageEnglish
Pages (from-to)670-675
Number of pages6
JournalJapanese Journal of Radiology
Issue number11
Publication statusPublished - 2014 Nov 18


  • Hepatocellular carcinoma
  • Indwelling catheter system
  • System-i
  • Transcatheter arterial chemoembolization
  • Transcatheter arterial infusion

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Intermittent transcatheter therapy through a new indwelling catheter system for patients with hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this